- Three-year extension of collaboration to use
genomics to accelerate drug discovery -
- The range of therapeutic areas and genomic
data insights will be expanded and the companies will also explore
using genomic risk to better define patient subgroups -
OXFORD,
England, July 16, 2024 /PRNewswire/
-- Genomics plc (Genomics), a healthcare company transforming
health through the power of genomics today announced a three-year
extension of the company's collaboration with Vertex
Pharmaceuticals Incorporated (Vertex) (Nasdaq: VRTX) to use
human genetics and machine learning to improve the discovery and
development of new precision medicines. The partnership, which
began in 2018, was previously extended in 2021. The collaboration
will now run until 2026.
The companies have been working together to support Vertex's
efforts to develop transformative medicines for serious diseases.
To date, Genomics' work has focused on using improved understanding
of human genetics to pinpoint causal disease pathways and
processes, and to identify novel targets in known and newly
identified pathways.
As part of the extension, Genomics will expand the range of
genomic insights it uses to support this work and expand the number
of therapeutic areas under study. The partnership will now also
explore using Genomics' proprietary genetic tools to improve
identification of patient populations and to de-risk the selection
of biomarkers for measuring early readout of drug efficacy.
Mark Bunnage, Senior Vice
President and Head of Global Research, Vertex:
"Vertex's leading-edge discovery teams and R&D capabilities,
and Genomics' world class scientists, are at the forefront of using
insights into human genetics to identify the most promising targets
and advance them into medicines for patients. This collaboration
has been valuable and productive, and we're excited to continue and
expand our transformative work right across the drug development
pathway."
Professor Sir Peter Donnelly
FRS, FMedSci, Founder and Chief Executive Officer, Genomics
plc:
"We are proud to extend our partnership with Vertex once again.
Our unique genomic data platform has meant that together, we have
discovered novel genetically-validated targets with the potential
to address diseases of high unmet medical need. Vertex is rightly
recognized for its innovative pipeline and track record in
developing treatments for serious diseases, which benefit the
patients, families, and healthcare systems coping with these often
life-threatening conditions. We are delighted to continue working
with them to drive precision medicine approaches where treatments
are tailored and delivered to those most likely to benefit."
For more information on Genomics plc and Vertex, visit
www.genomicsinc.com and https://www.vrtx.com/.
Contact
Genomics plc
BAM for Genomics plc
genomicsplc@bambybig.agency
About Genomics plc
Founded in 2014 by four
world-leading statistical and human geneticists at the University of Oxford, Genomics plc is a pioneering
healthcare company that uses large-scale genetic information to
bring new understanding about the genetic risk of common diseases
and disease processes to enterprises across the employer,
healthcare, insurance and life sciences industries. Genomics
collaborates with some of the world's leading organizations,
helping them to predict, prevent, treat and cure disease using its
proprietary algorithms and databases – reducing the human and
financial cost of critical diseases like cancer and diabetes. For
additional information about Genomics, please visit
www.genomicsinc.com, LinkedIn or X.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genomics-plc-announces-new-extension-and-expansion-of-drug-discovery-collaboration-with-vertex-302195072.html
SOURCE Genomics plc